What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2023-09-25 compared with 2022-09-28 · 58 added, 32 removed, 1 unchanged (99% of the section changed)

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

common stock trades on the OTCQB system under the symbol “ ALMU .” Our CUSIP number is 00776X.

should be aware that over-the-counter market quotations may reflect inter-dealer prices, without retail mark-up, mark-down or commissions

and may not necessarily represent actual transactions.

The high and low bid quotations for our shares of our common stock for each full

quarterly period within the two most recent fiscal years are (prices set forth below represent inter-dealer quotations, without retail

markup, markdown or commission and may not be reflective of actual transactions):

Quarter ended September 30, 2021

Quarter ended December 31 2021

Quarter ended March 31, 2022

Quarter ended June 30, 2022

Quarter ended September 30, 2020

Quarter ended December 31 2020

Quarter ended March 31, 2021

Quarter ended June 30, 2021

of September 27, 2022, the last reported sale price of our Common Stock on the OTCQB was $N/A per share.

Market for Registrant’s Common

Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our common stock trades on the OTCQB system under

the symbol “ALMU.” Our CUSIP number is 00776X.

There is currently limited trading volume for our Common Stock.

Holders of Record

of September 21, 2023, we had 12,167,930 shares of our common stock outstanding held by approximately 126 stockholders of record.

have never paid any cash dividends on our capital stock and do not anticipate paying any cash dividends on our common stock in the foreseeable

We intend to retain future earnings to fund ongoing operations and future capital requirements.

Any future determination to pay

cash dividends will be at the discretion of our board of directors and will be dependent upon financial condition, results of operations,

capital requirements and such other factors as the board of directors deems relevant.

Sales of Unregistered Securities

the period covered by this annual report, the Company has not issued unregistered securities to any person, except as described below.

None of these transactions involved any underwriters, underwriting discounts or commissions, except as specified below, or any public

offering, and, unless otherwise indicated below, the Registrant believes that each transaction was exempt from the registration requirements

of the Securities Act by virtue of Section 4(a)(2) thereof and/or Rule 506 of Regulation D promulgated thereunder, and/or Regulation

S promulgated thereunder regarding offshore offers and sales.

All recipients had adequate access, though their relationships with the

Registrant, to information about the Registrant.

July 1, 2021, we sold an additional 115,000 common stock shares at a purchase price of $2.00 per share in a private placement

offering for net proceeds (after deducting offering costs of $23,070) of $206,930 and issued 11,500 warrants to purchase common

stock to GP Nurmenkari Inc., who acted as the placement agent for this private placement offering.

Dividend Policy

We have never paid any cash dividends on our

capital stock and do not anticipate paying any cash dividends on our common stock in the foreseeable future.

We intend to retain future

earnings to fund ongoing operations and future capital requirements.

Any future determination to pay cash dividends will be at the discretion

of our board of directors and will be dependent upon financial condition, results of operations, capital requirements and such other

factors as the board of directors deems relevant.

Recent Sales of Unregistered Securities

During the periods covered by this Report, we

have not issued unregistered securities to any person, except as described below.

None of these transactions involved any underwriters,

underwriting discounts or commissions, except as specified below, or any public offering, and, unless otherwise indicated below, the

Registrant believes that each transaction was exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2)

thereof and/or Rule 506 of Regulation D promulgated thereunder, and/or Regulation S promulgated thereunder regarding offshore offers

All recipients had adequate access, though their relationships with the Registrant, to information about the Registrant.

2021 Offering

On June 5, 2021, we issued 20,000 shares of common

stock pursuant to an advisory agreement.

On June 10, 2021, we issued an aggregate of 511,278

shares of common stock pursuant to three individual Advisory Agreements, which includes an additional 164,108 shares to Mr.

who is one of our directors.

On June 10, 2021, we issued an aggregate of 99,414

shares of common stock pursuant to an Omnibus Equity Agreement, pursuant to which each of the signatories pursuant thereto agreed to

convert his/her shares issuable under his/her respective Simple Agreements for Future Equity agreements into shares of our common stock

at the close of the Merger.

On June 10, 2021, we entered into an amended

advisor agreement with Mr.

DenBaars to issue an additional 164,108 for the consideration amount of $2,461.62 to take on additional advisor

On June 22, 2021, pursuant to the Merger, we

issued an aggregate of 4,100,000 shares of our Common Stock in exchange for all of the shares of Biond Photonics’ shares of capital

stock issued and outstanding immediately prior to the Merger.

On July 1, 2021, we sold 115,000 common

stock shares at a purchase price of $2.00 per share in a private placement offering for net proceeds (after deducting offering costs

of $23,070) of $206,930 and issued 11,500 warrants to purchase common stock to GP Nurmenkari Inc., who acted as the placement

agent for this private placement offering.

2022 Offering

On November 7, 2022,

we issued 150,000 shares of common stock to a consultant for providing consulting services to us.

On December 22, 2022,

we issued an aggregate of 517,000 shares of our common stock to 21 accredited investors, for aggregate gross proceeds of $1,551,000 (the

“2022 Private Offering”).

On January 10, 2023,

we held a second close of the 2022 Private Offering, pursuant to which we issued an aggregate of 214,667 shares of our common stock for

aggregate gross proceeds of $644,000.

On March 31, 2023, we

held the third closing of the 2022 Private Offering, pursuant to which we issued an aggregate of 715,665 shares of our common stock for

aggregate gross proceeds of $2,147,000.

On May 10, 2023, we

held the final closing of the 2022 Private Offering, pursuant to which we issued an aggregate of 570,166 shares of our common stock for

aggregate gross proceeds of $1,710,500.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity